The results reflect the complex remodeling of the TME by cancer cells in the tumor and suggest that cancer metabolic reprogramming via VDAC1 depletion targets both the cancerous and stromal compartments within a tumor—a relation that may offer therapeutic potential. This evidence concerns the gene VDAC1 and cancer.